Goldman Sachs: Gazprom supply 2EU to increase by 10% 2015
Goldman Sachs: Gazprom supply to EU to increase by 10% 2015
Экспорт «Газпрома» в Европу в 2015 году может вырасти на 10%
Это произойдет из-за падения цен на российский газ, считают в Goldman Sachs
Also show me another biotech company with a phase 3 trial, outome EPIC study results within few months and 2 ph 2 trials with a PPS at 0.50. It is totally rediculous! It is priced as if MSTX has nothing in the pipeline and that is utter nonsense.
I am convinced that the price will start to rise hence so do believe the instuts as you mentioned.
A penny biostock with a phase 3, and plenty in the pipeline. And the fantastic news from 2 days ago.
Granted we are not there yet with results but they sure look promising.
Let's keep moving higher afterall results are expected Q1 2016 and that is not too far away anymore.
MDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer
Data Supporting Expanded Prognostic Application of Epigenetic Test Presented at the ASCO Genitourinary Cancers Symposium 2015
IRVINE, CA, and HERSTAL, BELGIUM - March 2, 2015 - MDxHealth SA (Euronext: MDXH.BR), today announced that data demonstrating the prognostic value of its ConfirmMDx® for Prostate Cancer genes and technology was presented at the ASCO Genitourinary Cancers Symposium 2015 in Rosen Shingle Creek, Orlando, Florida, USA (February 26-28, 2015). The data support the ability to predict the presence of clinically significant cancer in biopsy-negative patients based on the DNA hypermethylation of the biomarkers in the ConfirmMDx test.
ConfirmMDx for Prostate Cancer is an epigenetic test that was developed and validated to rule out the presence of undetected cancer in men with benign prostate biopsy results. This is achieved by measuring the intensity of DNA hypermethylation of the three ConfirmMDx biomarkers in histologically benign tissue. This study was designed to evaluate if those patients testing positive for ConfirmMDx could be further stratified for the risk for clinically significant cancer. A total of 102 patients (12 cores per patient), 20 with no cancer, 46 with Gleason score 6 prostate cancer and 36 with Gleason score 7 prostate cancer were tested with the ConfirmMDx test. Gleason score (GS) is the current standard pathological classification for prostate cancer aggressiveness. The results showed that the intensity of the DNA hypermethylation in benign needle biopsy cores is higher in patients with GS7 cancer compared to those with GS6 cancer alone. These findings support the feasibility of an algorithm that is sensitive to the GS of undetected foci of aggressive prostate cancer and could translate into a prognostic score to help stratify patients eligible for active surveillance from those who may benefit from earlier intervention.
"For all three ConfirmMDx biomarkers, we observed a positive correlation between the highest level of DNA hypermethylation in the adjacent benign cores with the cancer cores from the same patient. Interestingly, for each marker, the GS6 cores from the group with clinically significant cancer (GS7) showed significantly higher levels of DNA hypermethylation than the group with only GS6 cancer," reported Sandra M. Gaston PhD, Director of Urological Research at New England Baptist Hospital and Director of the Molecular Biomarkers Research Laboratory in the Department of Pathology and Laboratory Medicine at Tufts Medical Center in Boston. "These results suggest that risk stratification predicting the presence of clinically significant cancer in biopsy-negative patients based on the DNA hypermethylation of the ConfirmMDx genes is feasible."
"These data clearly support the prognostic power of the ConfirmMDx genes. The addition of a risk score for ConfirmMDx methylated patients, which enhances the test's positive predictive value, will provide deeper insights into a patient's risk for undetected clinically significant cancer," stated Dr. Jan Groen, CEO of MDxHealth. "The urology community has widely adopted ConfirmMDx for its ability to reduce unnecessary repeat biopsies, and these data will further augment the assay's clinical utility by aiding in the identification of patients who may benefit from early detection and treatment."
Revenue and Income
Total company revenues for the full year ended December 31, 2014, increased by 54% to $11.7 million, compared to total revenues of $7.6 million for the prior year. Revenue from ConfirmMDx for Prostate Cancer represented 70% of total Q4 revenues compared to 76% in the same quarter last year. Total revenues for Q4 2014 were $3.4 million compared to $1.6 million during the same period in 2013. The increase in Q4 2014 revenues compared to the prior period was due to increased sales of ConfirmMDx and royalty and milestone payments from Exact Sciences. For the full year, ConfirmMDx for Prostate Cancer accounted for 80% of the company's revenue, compared to only 50% in 2013.
At the end of 2014, MDxHealth received the Local Coverage Determination (LCD) for Medicare reimbursement of ConfirmMDx for Prostate Cancer through Palmetto GBA. The LCD not only sets the reimbursement rate for Medicare patients, but also establishes reimbursement for Medicare Advantage patients covered by private commercial payors. By virtue of the Center for Medicare and Medicaid Services policies, payors contracted to offer Medicare Advantage programs are obliged to honor the LCD and price established. MDxHealth will also pursue direct contracts with these payors to cover ConfirmMDx testing for their non-Medicare patient population under the age of 65 years old. The Medicare coverage decision did not impact 2014 cash collections, given the timing of the approval. However, the company expects the Medicare coverage decision for the ConfirmMDx for Prostate Cancer to improve cash collections going forward. As noted in previous press releases, the growing adoption of the test by new prescribing urologists across the U.S. will continue to result in a growing number of new payors, thus also increasing the group of non-contracted, third party payors. This could lead to continued delays in collections and revenue recognition among those payors.
ConfirmMDx revenue increased 152% from $3.7 million to $9.4 million in 2014
ConfirmMDx revenue for Q4 doubled to $2.4 million compared to $1.2 million in the same period last year
Total full year revenue increased to $11.7 million in 2014 versus $7.6 million in 2013
Recorded a 76% increase in annual ConfirmMDx case volume, with 12,300 patients tested in 2014 compared to nearly 7,000 patients tested in 2013
In Q4, ConfirmMDx case volume increased 46% to more than 3,300 tests, compared to approximately 2,300 tests in Q4 2013
Published ConfirmMDx clinical utility study in the journal of in American Health and Drug Benefits
Published ConfirmMDx DOCUMENT validation study in the Journal of Urology
Signed marketing agreements, with Long Island Pathology, Inc., American Pathology Partners, and Miraca Life Sciences (MLS) to co-promote ConfirmMDx
Signed exclusive distribution agreement with Teva Pharmaceutical Ltd. for Israel
Signed reimbursement agreements with PPO providers Prime Health Services, Inc., Galaxy Health Network Ancillary Care Services (ACS), and Consilium, LLC
Palmetto GBA issued a Medicare coverage determination (LCD) for ConfirmMDx
Other Business Activities
Raised $15 million in new equity funding via a private placement in November
MDxHealth and HistoGeneX N.V. awarded $1.8 million (#$%$1.3 million) from the Flemish Institute for the Promotion of Innovation by Science and Technology (IWT)
MDxHealth Licensee Exact Sciences received FDA approval and Medicare coverage for its Cologuard® colon cancer screening assay and started commercialization in Q4
Events after the Reporting Period
MDxHealth received the 2014 Euronext Best BEL Small Company Performer Award
MDxHealth licensed epigenetic technology to Oncgnostics GmbH for cervical cancer test
You're welcome Joethius, because of the low volume on the OTC market is why I suggested to buy on Euronext . There is enough liquidity and now that it's trading above #$%$5 more instuts can enter. Currently 3 analysts have covered this stock with a target of 6.50 Euro, but I suspect they will raise it as soon as the quarterly numbers show progressive sales both coming from CG as well as their own prostate cancer test ConfirmMDX.
Joethius, MDXH trades on Euronext Brussels under ISIN BE0003844611
I don't know if your trading platform allows you to trade other exchanges but it should. Same as I can buy any stock around the world. If not your broker will know how to buy it.
You're a smart man and I wish you good luck.
I told you I'd be back...
MDXH.BR just hit #$%$5
399 11/02/2015 17:14:36 CET 5.00 300.00 Exchange Continuous
398 11/02/2015 17:14:36 CET 5.00 800.00 Exchange Continuous
397 11/02/2015 17:14:36 CET 5.00 900.00 Exchange Continuous
396 11/02/2015 17:14:26 CET 5.00 800.00 Exchange Continuous
395 11/02/2015 17:14:26 CET 5.00 900.00 Exchange Continuous
394 11/02/2015 17:13:18 CET 5.00 560.00 Exchange Continuous
393 11/02/2015 17:13:18 CET 5.00 900.00 Exchange Continuous
392 11/02/2015 17:12:37 CET 5.00 900.00 Exchange Continuous
391 11/02/2015 17:12:31 CET 5.00 830.00 Exchange Continuous
390 11/02/2015 17:12:31 CET 5.00 150.00 Exchange Continuous
389 11/02/2015 17:12:28 CET 5.00 750.00 Exchange Continuous
388 11/02/2015 17:12:24 CET 5.00 100.00 Exchange Continuous
387 11/02/2015 17:12:24 CET 5.00 900.00 Exchange Continuous
384 11/02/2015 17:12:18 CET 5.00 500.00 Exchange Continuous
383 11/02/2015 17:12:18 CET 5.00 510.00 Exchange Continuous
382 11/02/2015 17:12:18 CET 5.00 250.00 Exchange Continuous
381 11/02/2015 17:12:18 CET 5.00 225.00 Exchange Continuous
380 11/02/2015 17:12:18 CET 5.00 900.00 Exchange Continuous
379 11/02/2015 17:12:18 CET 5.00 337.00 Exchange Continuous
378 11/02/2015 17:12:18 CET 5.00 900.00 Exchange Continuous
377 11/02/2015 17:12:18 CET 5.00 2,990.00 Exchange Continuous
376 11/02/2015 17:12:18 CET 5.00 1,500.00 Exchange Continuous
375 11/02/2015 17:12:18 CET 5.00 100.00 Exchange Continuous
374 11/02/2015 17:12:18 CET 5.00 1,828.00 Exchange Continuous
373 11/02/2015 17:08:33 CET 4.99 550.00 Exchange Continuous
372 11/02/2015 17:08:33 CET 4.993 450.00 Exchange Continuous
371 11/02/2015 17:07:04 CET 5.00 1,000.00 Exchange Continuous
370 11/02/2015 17:04:57 CET 5.00 950.00 Exchange Continuous
369 11/02/2015 16:58:24 CET 5.00 60.00 Exchange Continuous
368 11/02/2015 16:58:24 CET 5.00 400.00 Exchange Continuous
367 11/02/2015 16:58:24 CET 5.00 26.00 Exchange Continuous
366 11/02/2015 16:58:24 CET 5.00 717.00 Exchange Continuous
365 11/02/2015 16:58:24 CET 5.00 500.00 Exchange Continuous
364 11/02/2015 16:58:24 CET 5.00 872.00 Exchange Continuous
363 11/02/2015 16:58:24 CET 5.00 150.00 Exchange
361 11/02/2015 16:57:31 CET 5.00 172.00 Exchange Continuous
360 11/02/2015 16:57:31 CET 5.00 100.00 Exchange Continuous
359 11/02/2015 16:57:31 CET 5.00 400.00 Exchange Continuous
358 11/02/2015 16:57:31 CET 5.00 28.00 Exchange Continuous
354 11/02/2015 16:55:23 CET 5.00 400.00 Exchange Continuous
353 11/02/2015 16:55:23 CET 5.00 600.00 Exchange Continuous
352 11/02/2015 16:55:16 CET 5.00 100.00 Exchange Continuous